Abstract | INTRODUCTION:
Paclitaxel ( Taxol) is a drug derived from the bark of the Pacific yew tree and is widely used in cancer treatment, especially for breast, ovarian, and lung cancers. It has not previously been reported to induce lupus. CASE: DISCUSSION: The diagnosis of lupus was confirmed by the initial skin appearance, elevated levels of antinuclear antibodies, recurrence on reintroduction, and biopsy results. To our knowledge, it is the first case reported of paclitaxel-induced lupus.
|
Authors | Alain Lortholary, Myriam Cary-Ten Have Dallinga, Claude El Kouri, Nadine Morineau, Jean-François Ramée |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
Vol. 36
Issue 9 Pt 1
Pg. 1207-8
(Sep 2007)
ISSN: 0755-4982 [Print] France |
Vernacular Title | Lupus induit par le paclitaxel. |
PMID | 17521858
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Antinuclear
- Antineoplastic Agents, Phytogenic
- Recombinant Proteins
- epoetin beta
- Erythropoietin
- betamethasone-17,21-dipropionate
- Betamethasone
- Paclitaxel
|
Topics |
- Aged
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Antibodies, Antinuclear
(analysis)
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Betamethasone
(administration & dosage, analogs & derivatives, therapeutic use)
- Biopsy
- Drug Therapy, Combination
- Erythropoietin
(administration & dosage, therapeutic use)
- Female
- Humans
- Lupus Erythematosus, Cutaneous
(chemically induced, diagnosis, drug therapy, immunology, pathology)
- Ovarian Neoplasms
(drug therapy)
- Paclitaxel
(adverse effects)
- Recombinant Proteins
- Recurrence
- Skin
(pathology)
- Treatment Outcome
|